Kiniksa Pharmaceuticals Provides Corporate and Portfolio Update
09. Januar 2023 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
– ARCALYST® (rilonacept) Q4 2022 and full-year 2022 net product revenue of $39.9 million and $122.5 million, respectively (unaudited) – – 2 of 3 cohorts enrolled in KPL-404 Phase 2 trial in...
Kiniksa Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
03. Januar 2023 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday,...
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2022 Biotech SMID Cap Conference
30. November 2022 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Bank of America...
Kiniksa Pharmaceuticals to Present at Evercore ISI 5th Annual HealthCONx Conference
23. November 2022 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Evercore ISI 5th Annual...
Kiniksa Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
01. November 2022 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
– ARCALYST® (rilonacept) Q3 2022 net revenue of $33.4 million –– RHAPSODY long-term extension data demonstrated rilonacept treatment beyond 18 months resulted in continued treatment response (Hazard...
Kiniksa Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 1, 2022
31. Oktober 2022 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, November 1, 2022,...
Kiniksa Pharmaceuticals Announces Closing of Global License Agreement with Genentech for Vixarelimab
12. September 2022 08:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a portfolio of assets designed to modulate...
Kiniksa Pharmaceuticals to Present at 2022 Wedbush PacGrow Healthcare Conference
03. August 2022 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that its management will participate in a fireside chat at the 2022 Wedbush PacGrow...
Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
03. August 2022 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
– ARCALYST® (rilonacept) net revenue of $27.0 million in Q2 2022 – – ARCALYST full-year 2022 net revenue expected to be $115 - $130 million – – Upfront and near-term proceeds of $100 million...
Kiniksa Pharmaceuticals Announces Global License Agreement with Genentech for Vixarelimab
03. August 2022 07:29 ET
|
Kiniksa Pharmaceuticals, Ltd.
– Kiniksa to receive $100 million in upfront and near-term payments – – Kiniksa is eligible to receive development and commercial milestones as well as royalties on net sales – – Global license...